Mujtaba H. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mujtaba H. Shah has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jonathan Krakoff
Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, USA
2 shared publications- Paolo Piaggi
Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes Of Health Phoenix Arizona USA
2 shared publications - Alessio Basolo
Obesity and Lipodystrophy Center, Endocrinology Unit 1 University Hospital of Pisa Pisa Italy
1 shared publication - Carla Emilia Ibarra
M.D. Pontificia Universidad Catolica Del, Ecuador
1 shared publication Douglas C. Chang
Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
1 shared publication- Douglas C. Chang
Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases Phoenix Arizona USA
1 shared publication
Latest Publications
- Open Access
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5190
Anti-Inflammatory Potential of the Anti-Diabetic Drug Metformin in the Prevention of Inflammatory Complications and Infectious Diseases Including COVID-19: A Narrative Review
Metformin, a widely used first-line anti-diabetic therapy for the treatment of type-2 diabetes, has been shown to lower hyperglycemia levels in the blood by enhancing insulin actions. For several decades this drug has been used globally to successfully control hyperglycemia. Lactic acidosis has been shown to be a major adverse effect of metformin in some type-2 diabetic patients, but several studies suggest that it is a typically well-tolerated and safe drug in most patients. Further, recent studies also indicate its potential to reduce the symptoms associated with various inflammatory complications and infectious diseases including coronavirus disease 2019 (COVID-19). These studies suggest that besides diabetes, metformin could be used as an adjuvant drug to control inflammatory and infectious diseases. In this article, we discuss the current understanding of the role of the anti-diabetic drug metformin in the prevention of various inflammatory complications and infectious diseases in both diabetics and non-diabetics.
- 10 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5190
Open AccessAnti-Inflammatory Potential of the Anti-Diabetic Drug Metformin in the Prevention of Inflammatory Complications and Infectious Diseases Including COVID-19: A Narrative Review
Metformin, a widely used first-line anti-diabetic therapy for the treatment of type-2 diabetes, has been shown to lower hyperglycemia levels in the blood by enhancing insulin actions. For several decades this drug has been used globally to successfully control hyperglycemia. Lactic acidosis has been shown to be a major adverse effect of metformin in some type-2 diabetic patients, but several studies suggest that it is a typically well-tolerated and safe drug in most patients. Further, recent studies also indicate its potential to reduce the symptoms associated with various inflammatory complications and infectious diseases including coronavirus disease 2019 (COVID-19). These studies suggest that besides diabetes, metformin could be used as an adjuvant drug to control inflammatory and infectious diseases. In this article, we discuss the current understanding of the role of the anti-diabetic drug metformin in the prevention of various inflammatory complications and infectious diseases in both diabetics and non-diabetics.
- Open Access
- 3 March 2023
- Published by University Library System, University of Pittsburgh in International Journal of Medical Students
- p. S241
Exploring the Disproportionate Impact of COVID-19 in Older Adults in Canada
Introduction: Many patients recovered from Covid-19 without requiring any critical treatment, vulnerable populations such as older people, especially those with comorbidities, are more likely to develop a severe infection and face higher mortality rates. Background: Why are older Adults are Higher Risk? The majority of older adults have comorbid conditions, which are associated with a higher risk for COVID-19. Many live in residential care homes, which have seen the highest number of COVID-19 cases due to tightly shared living spaces. With weakened immune systems, older adults living in poverty face additional challenges in protecting themselves from the virus, as it is difficult for them to comply with public health measures such as social distancing. 32.5% of individuals in the lowest income quartile were hospitalized due to COVID19, compared to only 11.4% of individuals from the highest income quartile. Methods: The data was retrieved from the Canadian MIS Database (CMDB) and the discharge abstract database (DAD). The CMDB contains financial and statistical operations information on public hospitals and regional health authorities across Canada. Case selection is based on COVID-19 diagnosis codes available in the International Statistical Classification of Diseases and Related Health Problems. Results: Elderly faced higher rates of hospitalization during the pandemic. The average length of hospital stay was also higher for older adults—hospitalizations of individuals under age 65 without comorbidity 41,707 with comorbidity 12,372. Hospitalizations of individuals 65 and older without comorbidity were 22,221 with comorbidity 24,731. Higher Hospitalization rates and issues of inequality in the healthcare system globally. As the pandemic progressed, hospitalization increased in number significantly. The average length of stay for individuals younger than age 65 without comorbidity is 7.7 days compared to 17.0 days in patients with comorbidity. The average full length of stay for individuals 65 and older without comorbidity was 13.2 days, While in patients with comorbidity 19.2 days. Older adults had higher in-facility death rates due to COVID-19 hospitalization. The in-facility death rate of individuals younger than 65 without comorbidity is 2.5%, With comorbidity at 12.9%. In-facility death rate of individuals 65 and older without comorbidity is 14.4%, with comorbidity at 23.2%. Conclusion: By analyzing and comparing various hospitalization rates for Canada, the precise data indicate that older adults have been disproportionately impacted by COVID-19. It is now important to determine the underlying structural issues that have caused this inequality to prioritize healthy aging.
- 3 March 2023
- Published by University Library System, University of Pittsburgh in International Journal of Medical Students
- p. S241
Open AccessExploring the Disproportionate Impact of COVID-19 in Older Adults in Canada
Introduction: Many patients recovered from Covid-19 without requiring any critical treatment, vulnerable populations such as older people, especially those with comorbidities, are more likely to develop a severe infection and face higher mortality rates. Background: Why are older Adults are Higher Risk? The majority of older adults have comorbid conditions, which are associated with a higher risk for COVID-19. Many live in residential care homes, which have seen the highest number of COVID-19 cases due to tightly shared living spaces. With weakened immune systems, older adults living in poverty face additional challenges in protecting themselves from the virus, as it is difficult for them to comply with public health measures such as social distancing. 32.5% of individuals in the lowest income quartile were hospitalized due to COVID19, compared to only 11.4% of individuals from the highest income quartile. Methods: The data was retrieved from the Canadian MIS Database (CMDB) and the discharge abstract database (DAD). The CMDB contains financial and statistical operations information on public hospitals and regional health authorities across Canada. Case selection is based on COVID-19 diagnosis codes available in the International Statistical Classification of Diseases and Related Health Problems. Results: Elderly faced higher rates of hospitalization during the pandemic. The average length of hospital stay was also higher for older adults—hospitalizations of individuals under age 65 without comorbidity 41,707 with comorbidity 12,372. Hospitalizations of individuals 65 and older without comorbidity were 22,221 with comorbidity 24,731. Higher Hospitalization rates and issues of inequality in the healthcare system globally. As the pandemic progressed, hospitalization increased in number significantly. The average length of stay for individuals younger than age 65 without comorbidity is 7.7 days compared to 17.0 days in patients with comorbidity. The average full length of stay for individuals 65 and older without comorbidity was 13.2 days, While in patients with comorbidity 19.2 days. Older adults had higher in-facility death rates due to COVID-19 hospitalization. The in-facility death rate of individuals younger than 65 without comorbidity is 2.5%, With comorbidity at 12.9%. In-facility death rate of individuals 65 and older without comorbidity is 14.4%, with comorbidity at 23.2%. Conclusion: By analyzing and comparing various hospitalization rates for Canada, the precise data indicate that older adults have been disproportionately impacted by COVID-19. It is now important to determine the underlying structural issues that have caused this inequality to prioritize healthy aging.
- 6 January 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (4) , 914-922
Lower insulin clearance is associated with increased risk of type 2 diabetes in Native Americans
Aims/hypothesis Impaired insulin clearance is implicated in the pathogenesis of type 2 diabetes, but prospective evidence remains limited. Therefore, we sought to identify factors associated with the metabolic clearance rate of insulin (MCRI) and to investigate whether lower MCRI is associated with increased risk of incident type 2 diabetes. Methods From a longitudinal cohort, 570 adult Native Americans without diabetes living in the Southwestern United States were characterised at baseline and 448 participants were monitored over a median follow-up period of 7.9 years with 146 (32%) incident cases of diabetes identified (fasting plasma glucose ≥7.0 mmol/l, 2 h plasma glucose [2-h PG] ≥11.1 mmol/l, or clinical diagnosis). At baseline, participants underwent dual-energy x-ray absorptiometry or hydrodensitometry to assess body composition, a 75 g OGTT, an IVGTT to assess acute insulin response (AIR), and a hyperinsulinaemic–euglycaemic clamp to assess MCRI and insulin action (M). Results In adjusted linear models, MCRI was inversely associated with body fat percentage (r = −0.35), fasting plasma insulin (r = −0.55) and AIR (r = −0.22), and positively associated with M (r = 0.17; all p < 0.0001). In multivariable Cox proportional hazard models, lower MCRI was associated with an increased risk of diabetes after adjustment for age, sex, heritage, body fat percentage, AIR, M, fasting plasma glucose, 2-h PG, and fasting plasma insulin (HR per one-SD difference in MCRI: 0.77; 95% CI 0.61, 0.98; p = 0.03). Conclusions/interpretation Lower MCRI is associated with an unfavourable metabolic phenotype and is associated with incident type 2 diabetes independent of established risk factors. Clinical trial registration numbers: ClinicalTrials.gov NCT00339482; NCT00340132 Graphical abstract
- 6 January 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (4) , 914-922
Lower insulin clearance is associated with increased risk of type 2 diabetes in Native Americans
Aims/hypothesis Impaired insulin clearance is implicated in the pathogenesis of type 2 diabetes, but prospective evidence remains limited. Therefore, we sought to identify factors associated with the metabolic clearance rate of insulin (MCRI) and to investigate whether lower MCRI is associated with increased risk of incident type 2 diabetes. Methods From a longitudinal cohort, 570 adult Native Americans without diabetes living in the Southwestern United States were characterised at baseline and 448 participants were monitored over a median follow-up period of 7.9 years with 146 (32%) incident cases of diabetes identified (fasting plasma glucose ≥7.0 mmol/l, 2 h plasma glucose [2-h PG] ≥11.1 mmol/l, or clinical diagnosis). At baseline, participants underwent dual-energy x-ray absorptiometry or hydrodensitometry to assess body composition, a 75 g OGTT, an IVGTT to assess acute insulin response (AIR), and a hyperinsulinaemic–euglycaemic clamp to assess MCRI and insulin action (M). Results In adjusted linear models, MCRI was inversely associated with body fat percentage (r = −0.35), fasting plasma insulin (r = −0.55) and AIR (r = −0.22), and positively associated with M (r = 0.17; all p < 0.0001). In multivariable Cox proportional hazard models, lower MCRI was associated with an increased risk of diabetes after adjustment for age, sex, heritage, body fat percentage, AIR, M, fasting plasma glucose, 2-h PG, and fasting plasma insulin (HR per one-SD difference in MCRI: 0.77; 95% CI 0.61, 0.98; p = 0.03). Conclusions/interpretation Lower MCRI is associated with an unfavourable metabolic phenotype and is associated with incident type 2 diabetes independent of established risk factors. Clinical trial registration numbers: ClinicalTrials.gov NCT00339482; NCT00340132 Graphical abstract
Thigh Adipocyte Size is Inversely Related to Energy Intake and Respiratory Quotient in Healthy Women
Objective: The relationship between adipocyte size and ad libitum energy intake has not been previously examined. This study hypothesized an inverse relationship between adipocyte size and daily energy intake (DEI).Methods: Seventy healthy adults (39 men and 31 women; BMI 30.0 [SD 6.3]) underwent dual‐energy x‐ray absorptiometry and subcutaneous fat biopsies from the abdomen and thigh. Osmium‐fixed adipocytes were sized with a Coulter counter. Volunteers self‐selected food from a vending machine paradigm as the only source of energy intake over 3 days as inpatients. Volunteers also had 24‐hour respiratory quotient (RQ) measured in a whole‐room indirect calorimeter.Results: In women, the large cell peak diameter of the thigh depot was greater than that of the abdominal depot (Δ = +15.8 μm; P < 0.0001). In women, thigh peak diameter was inversely associated with DEI (β = −264.7 kcal/d per 10‐μm difference; P = 0.03) after adjusting for demographics and body composition. The thigh peak diameter in women was associated with 24‐hour RQ (r = −0.47, P = 0.04) after adjusting for demographics, body composition, and 24‐hour energy balance. These associations did not extend to men or the abdominal depot.Conclusions: In women, thigh adipocyte size was associated with reduced DEI and 24‐hour RQ, indicating a special role for thigh fat in women. This depot‐specific sexual dimorphism indicates common regulation of energy intake and adipocyte size in the thigh region of women.
Thigh Adipocyte Size is Inversely Related to Energy Intake and Respiratory Quotient in Healthy Women
Objective: The relationship between adipocyte size and ad libitum energy intake has not been previously examined. This study hypothesized an inverse relationship between adipocyte size and daily energy intake (DEI).Methods: Seventy healthy adults (39 men and 31 women; BMI 30.0 [SD 6.3]) underwent dual‐energy x‐ray absorptiometry and subcutaneous fat biopsies from the abdomen and thigh. Osmium‐fixed adipocytes were sized with a Coulter counter. Volunteers self‐selected food from a vending machine paradigm as the only source of energy intake over 3 days as inpatients. Volunteers also had 24‐hour respiratory quotient (RQ) measured in a whole‐room indirect calorimeter.Results: In women, the large cell peak diameter of the thigh depot was greater than that of the abdominal depot (Δ = +15.8 μm; P < 0.0001). In women, thigh peak diameter was inversely associated with DEI (β = −264.7 kcal/d per 10‐μm difference; P = 0.03) after adjusting for demographics and body composition. The thigh peak diameter in women was associated with 24‐hour RQ (r = −0.47, P = 0.04) after adjusting for demographics, body composition, and 24‐hour energy balance. These associations did not extend to men or the abdominal depot.Conclusions: In women, thigh adipocyte size was associated with reduced DEI and 24‐hour RQ, indicating a special role for thigh fat in women. This depot‐specific sexual dimorphism indicates common regulation of energy intake and adipocyte size in the thigh region of women.